Morningstar Investor users sign in here.
We’re currently having some problems with our data feed. We apologise for any inconvenience.

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

  • Contact

    500 Arsenal Street
    Watertown MA 02472
    USA

    T: +1 617 607-0800

    E: jviera@enanta.com

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2024

    Employees

    145

Stocks News & Analysis

video

Impact of the supermarkets code of conduct

Morningstar Director of Equity Research Johannes Faul explains the impact of the political hot water that Coles and Woolworths face. 
stocks

Four cheap wide moat ASX stocks

We follow Buffett’s adage to find great companies trading at attractive prices. 
stocks

5 top US dividend shares from the best managers

These cheap dividend stocks are popular among highly rated concentrated fund managers.

Market Movers

Name
Last price
Change
% Change
Sayona Mining Ltd SYA 0.04 0.00 0.00%
The Star Entertainment Group Ltd SGR 0.42 0.00 0.00%
Zip Co Ltd ZIP 1.18 0.01 -0.84%
Renascor Resources Ltd RNU 0.11 0.02 26.51%
Imugene Ltd IMU 0.08 0.00 0.00%
Strickland Metals Ltd STK 0.14 0.02 12.50%
Droneshield Ltd DRO 1.12 0.18 18.52%
Telstra Group Ltd TLS 3.68 0.00 0.00%
Red 5 Ltd RED 0.43 0.01 1.18%
Evolution Mining Ltd EVN 4.16 0.29 7.49%